A biological perspective for personalising immunotherapies

Bookmark and Share
Published: 6 Dec 2017
Views: 1877
Rating:
Save
Dr Tom Lillie - Head of European Clinical Development, MSD, London, UK

Tom Lillie talks to ecancer at EAPM 2017 in Belfast.

He spoke mainly about the development of pembrolizumab and the different responses in various tumour types. 

He also is pursuing an avenue of treatment by looking at tumours with high mutational loads.

Rather than ending up with a single drug for single case scenario, Dr Lille sees it as a particular combination of drugs to treat more specific cases.